GKCAS 2026 Annual Symposium

Kansas City, MO US
March 7, 2026

The Greater Kansas City Allergy Society (GKCAS) hosts an annual symposium to gather the providers, nurses, fellows and interested students and residents of the greater Kansas City area to provide education on the latest relevant topics in allergy and clinical immunology. The symposium provides didactic lectures by renowned experts on relevant topics.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Greater Kansas City Allergy Society (GKCAS).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 4 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 4 contact hours.

Commercial Support
This activity is supported in part by an independent medical education grant from Genentech, a member of the Roche Group.

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals

Learning Objectives

At the conclusion of this activity learners should be able to…

1. Diagnose food allergy using current evidence-based approaches, including component-resolved diagnostics, skin testing, and oral food challenges.
2. Compare and contrast available treatment options for food allergy, including OIT, SLIT, EPIT, and FDA-approved biologics, and identify appropriate candidates for each.
3. Describe the evidence supporting complementary and alternative medicine (CAM) modalities in allergic disease and counsel patients regarding their safety and efficacy.
4. Apply current consensus criteria for diagnosing mast cell activation syndrome and systemic mastocytosis.
5. Differentiate between primary, secondary, and idiopathic causes of mast cell activation and outline evidence-based management strategies.
6. Implement up-to-date protocols for evaluating and delabeling drug allergies, including risk stratification and direct oral challenge when appropriate.
7. Integrate new therapeutic and diagnostic advances into daily practice to improve patient outcomes and efficiency of allergy care.
8. Communicate more effectively with patients about novel treatment options and alternative approaches, fostering shared decision-making and patient trust.
9. Recognize and overcome barriers—such as payer restrictions or limited training—that impede adoption of modern allergy therapies.
10. Demonstrate increased confidence and competence in delivering comprehensive, individualized allergy management based on current evidence and best practices.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Course opens: 
03/07/2026
Course expires: 
12/31/2026
Event starts: 
03/07/2026 - 8:50am CST
Event ends: 
03/07/2026 - 2:00pm CST
Rating: 
0

Greater Kansas City Allergy Society 2026 Annual Symposium
March 7, 2026

Intercontinental, Country Club Plaza, Kansas City
All CME sessions will be held in the Salon III
Exhibits will be available in the Salon II

8:20 - 8:50 am Registration and Vendor Exhibits
            
8:50 - 9:00 am Welcome and Introduction

9:00 - 9:50 am David Khan, M.D.: What’s New in Antibiotic Allergies?

9:50 - 10:00am Q&A

10:00am-10:50am Cem Akin, M.D., Ph.D.: Mast Cell Disorders 

10:50-11:00am Q&A

11:00am-11:50am Matthew Greenhawt, M.D.: Treating IgE-Mediated Food Allergy

11:50 - 12:00pm    Q&A

12:00 - 12:30pm    Lunch and Vendor Exhibits

12:30 - 1:20pm Gary Soffer, M.D.: The Myth of the Boosted Immune System

1:20 - 1:30pm Q&A

1:30pm – 2:00pm Final Announcements and Adjournment

InterContinental Kansas City at the Plaza
401 Ward Parkway
Kansas City, MO 64112
United States

All relevant financial relationships with ineligible companies have been mitigated.

Alice Chou, MD, Planner
Researcher: Novartis

Brynn Everist, MD, Planner
Advisor: Sanofi
Speaker: Sanofi

Marissa Love, MD, Planner
Researcher: Teva, Target Pharma Solutions, AstraZeneca, Celldex, Allergy Therapeutics

Cem Akin, MD, PhD, Speaker
Consultant: Blueprint Medicine, Cogent, Telios, Novartis
Researcher: Blueprint Medicine, Cogent, Telios

Matthew Greenhawt, MD, Speaker
Consultant: Aquestive
Speaker: ARS, Genentech
Advisor: Nutricia, DBV, Novartis, Aquestive, Bryn, Genentech, Allergy Therapeutics, ALK-Abello

The following have no relevant financial relationships with ineligible companies to disclose:
Maggie Barnthouse, MD, Planner
Mary Jacobson, MD, Planner
David Khan, MD, Speaker    
Gary Soffer, MD, Speaker

Available Credit

  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Please login or create an account to take this course.